James M Reuben
Overview
Explore the profile of James M Reuben including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
6906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kai M, Marx A, Liu D, Shen Y, Gao H, Reuben J, et al.
Sci Rep
. 2021 Nov;
11(1):22242.
PMID: 34782633
Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional...
12.
Yennurajalingam S, Basen-Engquist K, Reuben J, Fellman B, Shete S, Maddi R, et al.
Support Care Cancer
. 2021 Jul;
30(1):497-509.
PMID: 34331589
Purpose: Cancer-related fatigue (CRF) is the most frequent and debilitating symptom in patients with advanced cancer. There are limited effective treatments for CRF. The objective of this prospective longitudinal study...
13.
Semba T, Wang X, Xie X, Cohen E, Reuben J, Dalby K, et al.
J Natl Cancer Inst
. 2021 Jul;
114(1):97-108.
PMID: 34250544
Background: Although an immunosuppressive tumor microenvironment (TME) is key for tumor progression, the molecular characteristics associated with the immunosuppressive TME remain unknown in triple-negative breast cancer (TNBC). Our previous functional...
14.
Park J, Tacam M, Chauhan G, Cohen E, Gagliardi M, Iles L, et al.
Breast Cancer Res Treat
. 2021 Jul;
189(2):333-345.
PMID: 34241740
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment...
15.
Basu H, Wilganowski N, Robertson S, Reuben J, Cohen E, Zurita A, et al.
Prostate
. 2021 Jun;
81(12):799-811.
PMID: 34170017
Background: Most cancer cells are more glycolytic even under aerobic conditions compared with their normal counterparts. Recent evidence of tumor cell metabolism, however, shows that some tumors also increase mitochondrial...
16.
Li X, Kumar S, Harmanci A, Li S, Kitchen R, Zhang Y, et al.
Genome Med
. 2021 Apr;
13(1):70.
PMID: 33902690
Background: Inflammatory breast cancer (IBC) has a highly invasive and metastatic phenotype. However, little is known about its genetic drivers. To address this, we report the largest cohort of whole-genome...
17.
Cohen E, Jayachandran G, Gao H, Qiao W, Liu S, He J, et al.
Transl Lung Cancer Res
. 2020 Nov;
9(5):1974-1985.
PMID: 33209617
Background: Various methods of liquid biopsy through the sampling of blood in cancer patients allow access to minuscule amounts of tumor that can easily be sampled repeatedly throughout therapy. Circulating...
18.
Gironda D, Adams D, He J, Xu T, Gao H, Qiao Y, et al.
J Transl Med
. 2020 Nov;
18(1):413.
PMID: 33148307
Background: Cancer Associated Macrophage-Like cells (CAMLs) are polynucleated circulating stromal cells found in the bloodstream of numerous solid-tumor malignancies. Variations within CAML size have been associated with poorer progression free...
19.
Cohen E, Jayachandran G, Hardy M, Venkata Subramanian A, Meng X, Reuben J
PLoS One
. 2020 Oct;
15(10):e0241123.
PMID: 33095819
Circulating tumor cells (CTC) isolated from the peripheral blood of cancer patients by a minimally invasive procedure provide surrogate markers of the tumor that can be repeatedly sampled. However, the...
20.
Goldstein L, Perez R, Yardley D, Han L, Reuben J, Gao H, et al.
Breast Cancer Res
. 2020 May;
22(1):52.
PMID: 32434589
An amendment to this paper has been published and can be accessed via the original article.